The importance of CD133 expression and treatment of thyroid cancer also continues to be established, with in vitro studies demonstrating radio-resistance in CD133+ papillary thyroid cancer cells and that CD133+ cells may be susceptible to novel therapeutic agents including all-trans retinoic acid, particularly in radio-resistant cells.16,17. The gene discussed is PROM1; the disease is thyroid gland carcinoma.